VIDEO: Identifying Risk Factors for Post-Stroke Epilepsy
Beate Diehl, MD, PhD, FRCP, discusses her research on post-stroke epilepsy.
Beate Diehl, MD, PhD, FRCP, discusses her research on post-stroke epilepsy.
Shaun Hussain, MD, MS, discusses a gap in health care provider knowledge that may contribute to the delay in the diagnosis and treatment of infantile spasms.
Elizabeth Thiele, MD, PhD discusses results from her research on cannabidiol in Lennox-Gastaut syndrome.
Clobazam had been previously identified as an AED with a significant interaction with CBD.
Justin Gover, CEO of GW Pharmaceuticals, the parent company of Greenwich Biosciences, discusses the status of the company’s cannabidiol product Epidiolex on the heels of positive results from several placebo-controlled trials in epileptic syndromes.
Number of AEDs and seizure frequency also influenced depression in people with epilepsy.
Concordant EEG/fMRI and ESI predicted outcomes with 100% sensitivity and specificity.
Adjunctive everolimus treatment has been found to significantly reduce frequency of treatment-resistant seizures in TSC.
The triple-validated SeLECT score may help identify patients suited for antiepileptic drug trials.
Results of the phase 3, placebo-controlled trial support previous findings from an expanded-access program.